350
Participants
Start Date
June 30, 2004
Primary Completion Date
June 30, 2007
Study Completion Date
June 30, 2007
esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Site 66, Huntsville
Site 57, Mobile
Site 46, Montgomery
Site 29, Phoenix
Site 15, Tucson
Site 3, Jonesboro
Site 22, Little Rock
Site 68, Carmichael
Site 55, Encinitas
Site 6, San Diego
Site 45, Santa Rosa
Site 25, Walnut Creek
Site 26, Denver
Site 1, Groton
Site 54, Hartford
Site 30, Trumbull
Site 34, Waterbury
Site 10, Aventura
Site 73, Fort Myers
Site 51, Leesburg
Site 49, Melbourne
Site 64, New Port Richey
Site 61, Ocala
Site 27, Palm Springs
Site 11, Pinellas Park
Site 75, Sarasota
Site 69, St. Petersburg
Site 70, Venice
Site 17, West Palm Beach
Site 50, Alpharetta
Site 5, Atlanta
Site 44, Decatur
Site 77, Douglasville
Site 9, Riverdale
Site 7, Savannah
Site 47, Boise
Site 24, Champaign
Site 20, Chicago
Site 76, Peoria
Site 58, Evansville
Site 39, Wichita
Site 59, Baton Rouge
Site 52, New Orleans
Site 53, Ann Arbor
Site 63, Kansas City
Site 32, Richmond Heights
Site 36, St Louis
Site 72, Billings
Site 21, Lincoln
Site 37, Reno
Site 65, Cary
Site 13, New Bern
Site 16, Winston-Salem
Site 60, Columbus
Site 67, Oklahoma City
Site 40, Tulsa
Site 62, Eugene
Site 41, Medford
Site 33, Portland
Site 18, Erie
Site 19, Philadelphia
Site 23, Pottstown
Site 31, Anderson
Site 35, Greer
Site 4, Chattanooga
Site 74, Conroe
Site 8, Corpus Christi
Site 71, Dallas
Site 42, Houston
Site 14, San Antonio
Site 38, Salt Lake City
Site 28, Norfolk
Site 12, Richmond
Site 56, Renton
Site 2, Seattle
Site 48, Spokane
Site 43, Tacoma
Solvay Pharmaceuticals
INDUSTRY